Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte : to Report Third Quarter Financial Results

10/13/2021 | 08:03am EST

Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 2, 2021.

The schedule for the press release and conference call/webcast is as follows:

• Q3 2021 Press Release:

November 2, 2021 at 7:00 a.m. ET
• Q3 2021 Conference Call: November 2, 2021 at 8:00 a.m. ET
• Domestic Dial-In Number: 877-407-3042
• International Dial-In Number: 201-389-0864
• Conference ID Number:

13724199

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13724199.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for 90 days.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.


ę Business Wire 2021
All news about INCYTE CORPORATION
11/19BMO Capital Starts Incyte at Market Perform With $75 Price Target
MT
11/18Novartis Said Considering Takeover in Biotech Sector
MT
11/09Incyte to Present at Upcoming Investor Conference
BU
11/08First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Stud..
AQ
11/04JMP Securities Adjusts Price Target on Incyte to $108 from $124, Keeps Market Outperfor..
MT
11/04More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at th..
BU
11/04SEC Brings Insider Trading Out Of The Shadows
AQ
11/03Oppenheimer Adjusts Price Target on Incyte to $109 from $110; Keeps Outperform Rating
MT
11/02INCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of..
AQ
11/02Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream - Form 8-K
PU
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2021 2 928 M - -
Net income 2021 525 M - -
Net cash 2021 2 043 M - -
P/E ratio 2021 28,9x
Yield 2021 -
Capitalization 14 959 M 14 959 M -
EV / Sales 2021 4,41x
EV / Sales 2022 3,50x
Nbr of Employees 1 773
Free-Float 98,5%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 67,72 $
Average target price 94,47 $
Spread / Average Target 39,5%
EPS Revisions
Managers and Directors
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Julian Charles Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INCYTE CORPORATION-22.14%14 959
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-41.09%23 827